Retatrutide, a triple agonist, significantly lowers blood pressure and improves lipid profile in RCT meta-analysis
Background
While GLP-1 and dual GLP-1/GIP receptor agonists have demonstrated benefits for blood pressure and lipid profiles, the comprehensive impact of retatrutide, a novel triple agonist targeting GLP-1, GIP, and glucagon receptors (GCGR), on these crucial cardiometabolic markers remained unclear. Understanding its full spectrum of effects is critical for addressing the multifaceted challenges of obesity, type 2 diabetes, and associated cardiovascular disease risk, where current therapies often fall short of comprehensive metabolic improvement.
Study Design
This meta-analysis systematically investigated retatrutide's effects on blood pressure and lipid levels by synthesizing data from randomized controlled trials (RCTs). Researchers conducted a comprehensive search across PubMed, Cochrane Library, Scopus, and ClinicalTrials.gov databases using relevant MeSH terms and keywords. For the meta-analysis, a random-effects model and the generic inverse variance method were employed to pool data and estimate the weighted mean differences (WMD) for various metabolic parameters across the included studies.
Results
The meta-analysis revealed that retatrutide treatment significantly improved several key cardiometabolic markers. It led to a substantial decrease in systolic blood pressure (SBP) with a WMD of -6.79 mmHg (95% CI: -8.36, -5.23, p < 0.0001, I2 = 20%). Similarly, diastolic blood pressure (DBP) was significantly reduced by a WMD of -2.46 mmHg (95% CI: -3.25, -1.67, p < 0.0001, I2 = 0%). Beyond blood pressure, retatrutide also profoundly impacted lipid levels:
Total cholesterol decreased by a WMD of -21.88 mg/dL (95% CI: -27.79, -15.97,
p < 0.0001,I2 = 84%). LDL-C saw a reduction of -13.10 mg/dL (95% CI: -16.10, -10.10,p < 0.0001,I2 = 47%), and triglycerides were lowered by -40.90 mg/dL (95% CI: -48.50, -33.30,p < 0.0001,I2 = 53%). Notably, retatrutide had no significant effect on HDL-C concentrations, with a WMD of -0.01 mg/dL (95% CI: -1.30, 1.27,p = 0.98,I2 = 0%).
Key Findings
- Retatrutide significantly decreased systolic blood pressure by -6.79 mmHg (
p < 0.0001). - Diastolic blood pressure was significantly reduced by -2.46 mmHg (
p < 0.0001). - Total cholesterol levels dropped by -21.88 mg/dL (
p < 0.0001). - LDL-C concentrations were lowered by -13.10 mg/dL (
p < 0.0001). - Triglyceride levels decreased by -40.90 mg/dL (
p < 0.0001).
Why It Matters
This meta-analysis provides compelling evidence that retatrutide offers significant benefits beyond its primary role in weight management, directly addressing critical cardiovascular risk factors. For individuals with obesity and metabolic syndrome, this means a single agent could potentially manage multiple comorbidities more effectively than existing dual agonists. Clinicians and biohackers should note the robust reductions in both blood pressure and atherogenic lipids, suggesting a powerful tool for comprehensive cardiometabolic health improvement. While specific dosing protocols were not the focus of this meta-analysis, the consistent efficacy across trials underscores its potential as a foundational therapy, likely integrated into existing weight loss and diabetes management protocols.
retatrutide
meta-analysis
blood-pressure
lipid-profile
obesity
type-2-diabetes